Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arrowhead Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ARWR
Nasdaq
2834
https://arrowheadpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arrowhead Pharmaceuticals Inc
Turnstone Biologics Appoints William Waddill to its Board of Directors
- Apr 16th, 2024 1:00 pm
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
- Apr 16th, 2024 12:57 pm
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
- Apr 7th, 2024 1:00 pm
Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
- Apr 4th, 2024 5:27 am
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Apr 1st, 2024 8:30 pm
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
- Mar 25th, 2024 12:00 pm
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
- Mar 11th, 2024 10:53 pm
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
- Mar 9th, 2024 4:29 am
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
- Mar 8th, 2024 12:30 pm
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
- Mar 6th, 2024 12:22 pm
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
- Mar 4th, 2024 12:30 pm
Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
- Feb 8th, 2024 11:33 am
ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year
- Feb 8th, 2024 11:00 am
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
- Feb 7th, 2024 3:42 pm
Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call
- Feb 7th, 2024 3:02 pm
Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ...
- Feb 6th, 2024 9:32 pm
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
- Jan 22nd, 2024 9:01 pm
Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years
- Jan 22nd, 2024 1:01 pm
Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
- Jan 18th, 2024 10:37 am
Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares
- Jan 9th, 2024 8:02 am
Scroll